Chapter 19: Sedative-Hypnotic and Anxiolytic Drugs

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome back to the Deep Dive.

Good to be here.

Today we are opening up the medicine cabinet, metaphorically speaking, of course.

Right.

We're gonna tackle a massive, and I mean a truly massive, topic in pharmacology.

That's a big one.

We've got a stack of research in front of us and it's all centered on one chapter.

We're looking at chapter 19 of Brenner and Stevens Pharmacology, sixth edition.

A very significant chapter.

We are talking about sedative, hypnotic, and angiolitic drugs.

Right.

And these are drugs that I think most people have heard of in one way or another.

Absolutely.

Valium, Xanax, Ambien.

These names have almost become verbs in our culture.

They're part of the lexicon now.

But our mission today isn't really to look at them culturally.

It's to get into the mechanics, the nuts and bolts.

We need to strip these drugs down to the molecular level.

We wanna understand why they work, why they can be so dangerous, and how the pharmacology has evolved.

It's a fascinating evolution, really, from the sledgehammers of the past to the more targeted therapies we have today.

It's really a story of science trying to solve two very distinct but very connected human problems.

Which are?

The inability to calm down and the inability to sleep.

Anxiety and insomnia.

Okay, so let's lay out the mission for today.

We're gonna break down this chapter, start to finish.

We're not skipping anything.

We could.

We have to understand the biology first, right?

The biology of anxiety, the biology of sleep.

Then we'll get into how the older drugs differ from the newer ones.

And the crucial safety profiles that every student, and frankly, every patient, should know about.

Absolutely essential.

But first, let's just clear up the definitions.

The chapter title itself groups them.

Sedative -hypnotic.

Now, to someone new to this, those might just sound like synonyms.

A very common misconception.

So are we dealing with one class of drug here, or is it two distinct categories?

That is the first trap students often fall into.

It's not necessarily about two different types of drugs.

It's more about, what, the effect.

It's often about one drug acting along a continuum.

A dose -dependent continuum.

Exactly.

Let's define the two poles of that continuum.

A sedative is an agent that reduces anxiety and exerts a calming effect.

Okay.

In clinical terms, we call that an anxiolytic effect.

Anxiolytic, literally anxiety -cutting.

Right, the goal there isn't to knock you out.

It's just to take the edge off so you can function during the day.

So sedation means calm.

Got it.

Now, move further down that line.

A hypnotic is a drug that induces drowsiness and promotes the onset and maintenance of sleep.

Okay, so with a hypnotic, the goal is to knock you out.

That's the goal.

And the source material really emphasizes that for many of these agents, especially the older ones we'll talk about, like barbiturates and even benzodiazepines, the only real difference between being calm and being asleep is the dose.

It's the milligram count in the pill,

precisely.

For many of these, it's a linear progression.

So you start with a low dose, you get sedation.

You increase the dose, you get hypnosis.

You increase it further.

You might hit general anesthesia, and if you keep going.

You get coma and then death.

Depending on the specific drug class, yes.

And that's a huge depending.

As we'll see, some drugs have a ceiling on that effect.

A built -in safety stop.

Sort of, while others do not.

And that distinction is, quite literally, a matter of life and death.

But the text does mention there are a few specific agents that kind of break this rule, correct?

Yes, and they're really interesting.

There are a few non -sedating anxiolytics.

So they treat anxiety without making you sleepy.

Which has long been the holy grail for daytime functioning.

We'll cover those at the very end of the deep dive.

Perfect, so here's our roadmap.

We're gonna follow the text's structure exactly.

Good idea, it builds logically.

We'll start with the context.

What even is anxiety and what is sleep from a biological perspective.

Then we move into the heavy hitters.

The drug classes.

Benzodiazepines, the old school barbiturates,

then antihistamines, the specific anti -insomnia agents like the Z drugs.

And finally, we'll wrap up with those non -sedating outliers.

You ready to dive in?

Let's do it.

Okay, section one.

The context of anxiety.

The book makes, I think, a fairly provocative statement right at the beginning.

It says anxiety isn't inherently a disease.

It's not, and that's a critical starting point.

It's an evolutionary survival mechanism.

So it's supposed to be there.

It is, think about it.

Anxiety is an adaptive response.

It prepares any organism to react to a challenge.

The classic fight or flight response.

That's it, exactly.

It involves a mood change, sure, apprehension or fear, but it's also a massive physiological upregulation.

Your body is kicking into high gear.

Total high gear.

Sympathetic nervous system arousal, hypervigilance.

If you're out on the savanna and you hear a twig snap behind you, you want anxiety.

You want your heart rate up.

You want your pupils dilated.

You want your blood pumping is what keeps you alive.

But we aren't usually running from tigers in the office anymore.

So when does this adaptive mechanism cross the line and become a medical disorder?

It becomes pathologic when it's chronic, when it happens without an appropriate external threat.

And crucially, when it impairs your ability to perform activities of daily living.

Right, when you can't go to work, you can't leave the house.

And the text points out that this isn't just feeling worried.

This is a profoundly physical experience.

Oh, it's a full body assault.

It's not just in your head.

We are talking about visceral organ dysfunction.

Like what?

Tachycardia, a racing heart,

excessive sweating, tremors, dizziness, severe gastrointestinal distress.

The mind is, in effect, convincing the body that it's in mortal danger, even when it isn't.

So neurologically, who is running this show?

What part of the brain is the command center for all this?

The text identifies the amygdala as the central player here.

The amygdala.

That's the almond -shaped structure deep in the temporal lobe, right?

That's the one, often called the fear center.

It acts as the central processing unit for fear and anxiety.

Specifically, it mediates something called the conditioned avoidance reaction.

Okay, let's unpack that term, conditioned avoidance.

What does the text mean by that?

They use a classic animal model to explain it, and it's a really clear example.

Imagine you have a lab rat.

Okay.

You show the animal a flashing light.

At first, that's a neutral cue, it doesn't mean anything on its own.

Right, just a light.

But if you follow that flashing light every single time, with a mild shock to the foot, a noxious stimulus, the animal starts to pay attention.

The amygdala connects the dots.

Precisely.

The amygdala learns to associate the light with the pain.

Eventually, you don't even need the shock anymore.

The light alone is enough.

The light alone triggers the full panic response.

The autonomic arousal, the racing heart, the behavioral fear, that is a conditioned response.

And the underlying mechanism for this learning is something called long -term potentiation, or LTP.

Yes, and this is so important.

LTP is essentially the strengthening of synaptic connections.

The neurons in the amygdala that fire together, wire together.

They physically change.

They physically change to lock in this memory of an adverse event.

It effectively creates a durable memory of fear.

That is a really powerful image.

The brain physically wiring itself for fear.

It is.

It creates what the book calls anticipatory anxiety.

You're not just reacting to a present threat.

You're reacting to the possibility of a threat based on this past programming.

And that's the core of so many anxiety disorders.

Once that wiring is established, it can be very, very difficult to dismantle.

Okay, so now that we have the biological basis, the text moves into classifying these disorders.

It gives a brief overview of treatment approaches, which is important because it sets the stage for which drugs we use and when.

Right, different disorders, different tools.

Let's run through these quickly.

First up, acute anxiety.

This is situational.

It's linked to a specific event, an illness, a separation, a stressful life event, like a divorce or losing a job.

So it has a clear beginning and hopefully an end.

Right, it's often self -limiting.

The text suggests that if you do need medication, a benzodiazepine is good for short -term relief because it works fast.

You have a crisis, you take the pill, the crisis feels manageable.

Okay, now contrast that with panic disorder.

Panic disorder is a whole different level of intensity.

These aren't just worries.

These are acute, terrifying episodes of impending doom.

The person feels like they're dying.

Literally, they think they're having a heart attack or suffocating.

The visceral symptoms are just off the charts.

Again,

for immediate, on -the -spot relief, you might use a high -potency benzodiazepine.

The text mentions alprazolam or clenazepam.

But you wouldn't keep a patient on that forever, would you?

No, and this is a key shift in modern practice that the text highlights.

For long -term maintenance, the first -line treatment is now antidepressants.

Specifically SSRIs, like fluoxetine.

Exactly.

You might use the benzo as a bridge therapy.

A bridge.

A bridge to get you through the first few weeks because the SSRI can take a month or more to kick in, but the goal is to move to the antidepressant for the long haul.

We see that pattern a lot.

Then benzos for the now, antidepressants for the later.

It's a very common strategy.

Okay, what about phobic disorders?

Things like specific phobias, spiders,

heights, or agoraphobia, the fear of public places.

It follows a pretty similar pattern.

Benzos for the acute symptoms.

Right, maybe to help a patient get through a session of exposure therapy.

But again, antidepressants are the long -term fix.

But there's an interesting exception mentioned for stage fright.

Ah, yes, performance anxiety.

The text mentions propanolol.

The beta blocker.

That seems odd.

Well, think about what's happening.

If you're a concert violinist or a public speaker, you don't want a benzodiazepine.

You don't want your brain sedated.

You need to be sharp.

Right, you need your wits about you.

You just want your hands to stop shaking and your heart to stop pounding out of your chest.

Propanol does that.

It blocks those peripheral physical symptoms without clouding the mind.

It's a very clever use of pharmacology.

Moving on to OCD, obsessive compulsive disorder.

This is characterized by obsessions, which are persistent intrusive thoughts and compulsions, which are repetitive behaviors to try and neutralize those thoughts.

And the treatment here.

The primary treatment is antidepressants and psychotherapy.

Benzos really aren't the main player here at all.

And GAD, generalized anxiety disorder.

GAD is chronic free -floating worry.

The patient worries about everything, money, health, work, the weather for months on end.

It's exhausting.

And the treatment strategy.

Again, the text notes that benzodiazepines can be used as that bridge therapy or intermittently during particularly bad patches.

But this is where we first see buspirone listed as a non -sedating alternative.

We'll get to that later.

And of course, SSRIs and SNRIs, like venlafaxine or duloxetine, are key for long -term management.

And finally,

PTSD.

Post -traumatic stress disorder.

Triggered by exposure to a severe traumatic event.

Here SSRIs are the primary pharmacological treatment.

And benzos.

They're used very cautiously.

Generally reserved only for specific symptoms like an exaggerated startle response.

They are not a cure for the underlying trauma itself.

Okay, so that's a good map of the anxiety landscape.

Now let's shift to the other side of the coin.

Sleep.

The text breaks down something it calls sleep architecture.

Right, and this is where the biology gets really, really interesting.

Sleep isn't just turning off the brain.

That's a huge misconception.

It's an active process.

Very active.

It's a reversible state of reduced consciousness with very specific, measurable brain wave patterns.

And we have two main types.

NREM and REM.

Non -rapid eye movement and rapid eye movement.

Correct.

NREM is further divided into four stages.

When you first doze off, you're in stage one and two, which is light sleep.

Your brain waves go from high frequency, low amplitude, which is the pattern of being awake and alert, to a lower frequency and a higher amplitude.

In stages three and four.

That is what we call slow wave sleep.

This is deep sleep.

Very low frequency, high amplitude waves on the EEG.

This is the physically restorative part of sleep.

When your body does its repairs.

Exactly, then we have REM sleep.

And REM is fascinating.

The text calls it paradoxical sleep.

It does.

Why paradoxical?

What's the paradox?

Because if you just look at the EEG, the brain wave recordings, it looks like the person is wide awake.

High frequency, just like being alert.

Exactly.

But at the same time, all of your voluntary muscles are paralyzed, except for your diaphragm and your eye muscle.

And your eyes are darting back and forth.

Right, rapid eye movements.

This is when vivid dreaming happens.

And we cycle through this, right?

It's not like we just go down a ladder from stage one to REM and stay there.

No, it's a very predictable cycle.

About every 90 minutes, a normal adult goes from stage one down to four, then back up through the stages to hit a period of REM.

You repeat this cycle multiple times a night.

The text highlights box 19 .1 and 19 .2, which talk about the insomnia pattern.

So what does bad sleep actually look like on one of these brainwave maps?

It's characterized by three main things.

First, prolonged sleep latency.

Latency meaning?

The time it takes you to actually fall asleep after you turn out the light.

Second, frequent nocturnal awakenings.

You can't stay asleep.

Tossing and turning.

Right.

And third, a reduction in total sleep time.

You just don't get enough hours.

Now here's where it gets really crucial for our discussion on drugs.

We take these pills to help us sleep, but do they give us normal sleep?

Do they restore that architecture?

That is the million dollar question.

And the text is very explicit about this.

The older drugs, benzodiazepines and barbiturates, they do help you sleep.

They decrease latency.

It's a but.

A huge but.

They suppress stage three slow wave sleep and they suppress REM sleep.

So you are unconscious, but you aren't getting the full restorative deep sleep or the dream sleep.

Exactly.

You're missing out on key parts of the cycle.

It's almost like a counterfeit version of sleep.

And what happens when you stop taking the drugs?

The brain tries to compensate.

You get something called REM rebound, intensely vivid, often disturbing dreams and nightmares and a very restless night.

However, the text points out this is a major advantage of the newer agents, the Z drugs like zolpidem.

Yes.

This is a key clinical distinction.

They do not significantly affect sleep architecture.

So they hope you fall asleep, but then they let your brain do its natural cycling thing.

That's the idea.

And it's a massive clinical advantage.

Before we leave the sleep context, what's happening neurologically?

Who is driving the sleep bus in the brain?

It's a complex interaction, but the book highlights two main areas,

the basal forebrain and the reticular formation.

The basal forebrain has cholinergic fibers that actively promote sleep, but the reticular formation is sort of the arousal center.

It acts as a gatekeeper for all this sensory information coming into your brain.

So when it's active, you're awake, you're processing the world.

Right.

And when the reticular nuclei become quiescent or quiet, the thalamus stops sending that sensory info up to the cortex and you fall asleep.

Okay, we have our context.

Anxiety and sleep are laid out.

Now let's get into the drugs themselves.

Section three, benzodiazepines,

the major drug class.

These are the heavyweights.

For decades, they were the go -to.

Named for their chemical structure, a benzene ring fused to a diazepine ring.

Let's start with pharmacokinetics.

How do they move through the body?

It starts with lipid solubility.

That's what determines how fast they work.

The more lipid soluble, the faster they cross the blood -brain barrier.

Exactly.

But the real story here and the part that always trips up students is metabolism.

This is figure 19 .1 in the text, and it's a critical one.

We have phase I and phase II metabolism.

Can you break this down for us?

Sure.

So most benzodiazepines undergo phase I oxidation in the liver.

This is catalyzed by the cytochrome P450 enzyme system.

Drugs like chloridized epoxide and diazepam, which is Valium, go through this phase I process.

And here's the kicker.

They're converted into active metabolites.

Active metabolites.

So the liver breaks them down, but the leftover pieces are still working drugs themselves.

Precisely, and not just working.

Some of them are very long acting.

For example, diazepam is converted to something called dysmethyldiazepam, which has a half -life that can be measured in days.

Days, yeah.

And this contributes to a very long duration of action and that very real risk of a hangover effect the next day or even the day after.

Okay, so that's phase I.

What happens in phase II?

Phase II is conjugation.

Essentially, the liver attaches another molecule, usually glucuronide, to the drug or its metabolite.

This makes it inactive and water -soluble.

So it can be easily excreted by the kidneys,

peed out.

Right, phase I modifies it, phase II packages it for disposal.

So phase I creates active leftovers, phase II cleans them up.

Generally, yes.

Now, here is the clinical pearl, the high -yield fact you have to know.

Some benzodiazepines bypass phase I entirely.

To skip the oxidation part.

They go straight to phase II conjugation.

The text calls them the clean drugs.

We can call them that.

The text lists them out.

Oxazepam, tamazepam, clonazepam, and lorazepam.

And why does this matter so much?

It matters immensely for the elderly.

As we age, our phase I oxidative capacity declines.

Our liver just isn't as good at it anymore.

But our phase II capacity stays relatively intact.

I see where this is going.

So if you give an elderly patient diazepam.

Their liver struggles with the phase I breakdown.

The drug and its long -acting active metabolites start to build up.

You get toxic accumulation, which leads to confusion, falls, and sedation that lasts way, way too long.

But if you give them lorazepam or tamazepam.

It goes straight to phase II, which their liver can still handle just fine.

They clear it much more safely and predictably.

There's a fantastic case study in the text that illustrates this perfectly.

Box 19 .3,

the case of the groggy grandmother.

It's a classic example.

It describes a 68 -year -old woman whose husband recently died.

Her doctor prescribes five milligrams of diazepam for her anxiety.

And she's taking it, but then she starts taking an extra one at night because she can't sleep.

Right.

And then her friends find her wandering around her assisted living facility in her nightgown, completely disoriented and confused.

And the reason was exactly what we just discussed.

Exactly.

Diazepam has those long -acting metabolites.

Her elderly liver couldn't clear them.

They just accumulated toxic levels.

And the solution.

Switching her to a drug with a much shorter half -life, like zolpidem, or using one of those phase II only benzos, like lorazepam or tamazepam.

So the take -home message for the elderly.

Avoid the long -acting face -eye drugs.

Remember the list?

Yeah.

Lorazepam, oxazepam, tamazepam.

There's a mnemonic for that.

You can remember that they are out the liver, cleared.

Oxazepam, tamazepam, lorazepam, clonazepam fits in there too.

I like that.

That's useful.

There's one other pharmacokinetic quirk mentioned in the text, enderohepatic cycling.

Yes.

This one's interesting and kind of sneaky.

Imagine you take a dose of diazepam.

Hours later, you eat a fatty meal, like a burger and fries.

OK.

Your gallbladder contracts to squirt bile into your intestine to help digest the fat.

Well, that bile contains some of the diazepam that had been stored there.

And gets reabsorbed into the blood.

Exactly.

So a patient might feel a second wave of sedation hours after their dose just from eating a meal.

Very tricky.

OK, let's move to the mechanism of action.

This is the core of it.

How do these drugs actually work at the receptor level?

The target is the GABA receptor chloride ion channel.

That is a mouthful.

It is.

It's a big protein complex made of five subunits, usually a combination of alpha, beta, and gamma subunits that form a pore, a channel, through the cell membrane.

And GABA, as we said, is the main inhibitory neurotransmitter, the brain's brake pedal.

Right.

When GABA binds to its spot on this receptor, the channel opens up, and chloride ions, which are negatively charged, rush into the neuron.

And that makes the neuron hyperpolarized.

Which means harder to fire.

It inhibits the neuron's activity.

So where do benzodiazepines fit in?

They bind to the same receptor complex, but, and this is absolutely critical, they do not bind where GABA binds.

They have their own separate binding site.

An allosteric site.

Yes, specifically at the interface between the alpha and gamma subunits.

So they aren't replacing GABA or mimicking it.

No, they potentiate GABA.

They're like a cheerleader for GABA.

When a benzo is attached to its site, it increases the affinity of GABA for its own receptor site.

It makes GABA stick better and work more effectively.

And mechanically, at the channel level, what actually changes?

It increases the frequency of the channel opening.

Frequency, that's the key word.

That is the word to underline.

With a benzo on board, every time GABA binds, the channel pops open more often than it would have without the benzo.

More pops, more chloride, more inhibition.

And because they require GABA to be present to work, they can't open the channel all by themselves,

this leads to what the book calls a sealing effect.

Can you explain the sealing effect?

Since the drug's effect relies on your body's own natural supply of GABA, there's a limit to how much CNS depression it can cause.

So you can't just keep depressing the system indefinitely.

Right, you can take a lot of benzodiazepines and you will certainly go to sleep, but you generally won't stop breathing or die, provided you haven't mixed them with another depressant, like alcohol or opioids.

The depression kind of plateaus.

Which is what makes them so much safer than the older drugs we'll get to later.

Much, much safer.

So what are the overall pharmacologic effects?

We go from sedation to hypnosis.

And eventually anesthesia, but as we said, benzos alone usually can't produce the deep level of anesthesia needed for major surgery.

They also cause a very specific type of memory loss.

Enterograde amnesia.

That's the inability to form new memories while the drug is active.

So you don't forget the past.

No, not retrograde.

You don't forget who you are, you just stop recording new information.

This is actually a desirable effect for an unpleasant procedure like a colonoscopy.

You don't wanna remember that.

Exactly, but it's a very problematic side effect for a student who takes one to calm their nerves and then tries to study for an exam.

They won't retain anything.

Nothing.

They also have anticonvulsant effects and they cause muscle relaxation.

Yes, the muscle relaxation is interesting.

It's not just from sedation in the brain, it's also from potentiating GABAs effects in the spinal cord.

Now the downside.

So let's talk about adverse effects.

The most common ones are extensions of the therapeutic effects.

Motor and coordination like being drunk.

Cognitive impairment, slowed thinking.

And that hangover effect we mentioned, especially with the long acting ones.

What about dependence and withdrawal?

It is a very real risk, especially with long -term use.

The body adapts and you develop physical dependence.

If you then stop the drug abruptly, you get a nasty withdrawal syndrome.

Which includes what?

Rebound anxiety, insomnia, irritability, tremors, in severe cases, seizures.

The text specifically calls out a brazillium or Xanax when it comes to withdrawal.

Yes, because it's high potency and relatively short acting, the withdrawal can be particularly abrupt and severe.

Seizures are a known risk with stopping alprazolam cold turkey.

These drugs must always be tapered slowly.

What happens if someone does overdose?

Is there a rescue drug, an antidote?

There is, a drug called Flumazenol.

And how does Flumazenol work?

It is a competitive antagonist.

It goes to that same benzodiazepine binding site on the GABA receptor, and it competitively kicks the benzo off.

It just boots it out of the way.

Exactly, and it can rapidly reverse the sedation.

It's an effective rescue for an overdose.

But there's a big, bold warning label on Flumazenol in the textbook.

Yeah, a huge warning.

If a patient is physically dependent on benzodiazepines, say they've been taking them daily for years for anxiety, and you slam them with a dose of Flumazenol.

You're instantly putting them into acute withdrawal.

The worst withdrawal imaginable.

You can precipitate life -threatening seizures and cardiac arrhythmias, so you have to be very, very certain the patient isn't a chronic user before you give it.

Before we leave benzos, let's head a few specific agents the text calls out.

We talked about alprazolam being high risk for dependence.

What about triazolam?

Triazolam is a very short -acting hypnotic, but it has a notorious reputation for causing rebound insomnia and amnesia.

In fact, the text notes that it's been banned entirely in the United Kingdom because of these significant psychiatric side effects like confusion and delirium.

And midazolam?

Midazolam is incredibly common.

It's used intravenously for procedural sedation, conscious sedation, and induction of anesthesia.

But the text brings up a fascinating and frankly chilling legal history here.

It does.

It relates to lethal injections.

When the US and Europe stopped allowing the sale of the opental for executions, some states switched to using midazolam as the first drug in their protocol.

And this went all the way to the Supreme Court.

It did.

The legal argument was that midazolam being a benzodiazepine with that sealing effect we discussed cannot reliably produce the deep coma -like state of anesthesia that a barbiturate can.

So the concern was that the inmate might not be fully unconscious and could still feel the pain of the subsequent drug.

Exactly, that it would constitute cruel and unusual punishment.

And what did the court decide?

In a very close five to four decision, they upheld the use of midazolam.

But the text adds a very dry but pointed comment.

What's that?

That this was the first time the Supreme Court had to consider a basic pharmacology question, and they effectively failed to answer it correctly, ignoring the fundamental pharmacological difference between a benzo and a barbiturate.

A very stark reminder of why understanding these mechanisms matters in the real world.

There's one new agent mentioned,

remimazolam.

Yes, the newest kid on the block.

It's very cleverly designed.

It has an ester linkage in its structure, similar to the opioid remifentanil.

And why is that useful?

That ester linkage allows it to be broken down very rapidly by enzymes called tissue esteroses, which are all over your blood and tissues.

This gives it an incredibly predictable, short duration of action, perfect for sedation procedures.

Okay, that's a very thorough look at the benzos.

Now let's step back in time.

Section four, barbiturates.

The old guard.

The open telophenobarbital, pentobarbital, these are the older and much more dangerous cousins in this family.

Why are they so much more dangerous?

It all comes back to the mechanism, right?

It all comes down to the mechanism.

Like benzos, they bind to the GABAI receptor, but they bind to a different allosteric site.

Okay, a different spot on the receptor, and what do they do from that spot?

Two crucial differences.

First, remember how benzos increase the frequency of the channel opening?

Right, more pops.

Barbiturates increase the duration of the channel opening.

They hold the door open for longer each time GABA binds.

Longer, not more often.

And the second difference.

This is the important one.

This is the killer.

At high doses, arbiturates can open the chloride channel directly, even without any GABA present.

They don't need the cheerleader.

They can kick the door down all by themselves.

That's the perfect analogy, and this means there is no sealing effect.

Which you can see in figure 19 .3.

The dose -response curve is just a straight, linear line heading down.

Exactly, you go from sedation to hypnosis to anesthesia to coma to respiratory depression and death.

There's no plateau.

And that's why they are so rarely used for anxiety or insomnia anymore.

The risk is just too high.

The therapeutic index is far too narrow.

The dose that puts you to sleep isn't that far from the dose that kills you.

They also have a problematic pharmacokinetic issue involving the liver.

Right.

Barbiturates are potent inducers of cytochrome P450 enzymes.

What does that mean, they induce them?

They ramp up the liver's production of these enzymes.

This has two consequences.

First, they accelerate their own metabolism, which leads to pharmacokinetic tolerance.

You need more drug to get the same effect.

And second.

They chew up other drugs faster too.

So if a patient is on,

say, warfarin or oral contraceptives, a barbiturate can make those drugs less effective.

And there's a specific contraindication mentioned in the text, porphyria?

Yes, a big one.

Barbiturates induce an enzyme involved in the synthesis of porphyrins.

If a patient has a genetic disorder called porphyria, giving them a barbiturate can trigger a massive, painful, and dangerous crisis.

Let's touch on a couple of specific agents.

Fiopental.

Ah, Fiopental.

The classic truth serum of old movies.

It's famous for being ultra -short acting.

It was the standard drug for inducing anesthesia for decades.

And its short duration is not because it gets metabolized quickly.

Correct.

It's due to redistribution.

Can you claim that?

You inject it intravenously.

It's super lipid soluble, so it floods into the brain within seconds.

Boom, the patient is unconscious.

But Dan.

As the blood continues to circulate, the drug quickly moves out of the brain and redistributes into other tissues, especially muscle and fat.

The brain levels plummet, and the patient starts to wake up, often just a few minutes later.

So the drug is still in their body, it's just not in their brain anymore.

Precisely.

Its effect is terminated by redistribution, not metabolism.

And the text notes, Fiopental is no longer available in the US, which, as we said, connects back to that whole lethal injection story.

That's right.

What about phenobarbital?

Phenobarbital is very long -acting.

Its use is now pretty much restricted to treating certain types of seizure disorders.

All right, moving on from the heavy eaters.

Section five, antihistamines.

Diffinhydramine, which is benadryl,

hydroxazine, doxepin.

We usually think of these for allergies.

Hay fever?

Why are they in a chapter on sedatives?

Because the first -generation ones are very good at crossing the blood -brain barrier.

And in the brain, they block H1 histamine receptors.

And histamine in the brain promotes wakefulness.

Exactly.

They also reduce the release of acetylcholine in the reticular activating system.

That system that acts as the brain's on switch.

Right.

So by dampening that arousal system, they cause sedation.

They're very popular for mild insomnia.

That's why almost every over -the -counter sleep aid is basically just diffinhydramine in a different box.

Pretty much.

They have less abuse potential than benzos, which is a big plus.

Okay, section six,

anti -insomnia agents.

This is where we get into the more modern drugs.

We touched on them earlier, the Z drugs.

Zolpidem, which is Ambien, Xalipon, which is Sonata,

and Azopaclone Lunesta.

The text makes it clear that these are chemically different from benzodiazepines.

They are.

Structurally, they're not benzos.

But they bind to the same GABA -A receptor complex.

The key difference, though, is that they are selective.

Selective in what way?

They show a high affinity for GABA -A receptors that contain the alpha -1 subunit.

And that alpha -1 subunit is thought to be primarily responsible for sedation.

That's the thinking.

And this selectivity seems to be the reason why they can induce sleep without messing up the REM and slow -wave stages as badly as the non -selective benzos do.

That's their main selling point.

It is.

Xalipon is mentioned as having a super short half -life.

Extremely short, about one hour.

It's marketed specifically for middle -of -the -night awakenings.

So you wake up at 3 a .m., you can't get back to sleep.

You take a Xalipon, and it helps you fall back asleep.

But it's pretty much gone from your system by the time your 7 a .m.

alarm goes off.

But safety -wise, these drugs aren't perfect.

The FDA has issued some pretty bizarre warnings about them.

Yes, for complex sleep behaviors.

This is serious stuff.

Sleep driving, sleep walking, sleep eating, making phone calls while completely asleep.

And the person had no memory of it the next day.

None at all.

It's rare, but it's serious enough that there's now a black box warning about it.

Okay, then we have an even newer class.

The orexin receptor antagonists.

Suver -excent and limber -excent?

What is orexin?

Orexin is a neuropeptide in the brain whose job is to promote wakefulness.

It's essentially the chemical signal that keeps the lights on.

So these drugs block orexin.

They do.

So instead of enhancing the sleep signal, like the GABA drugs do.

They're turning off the awake signal.

Precisely.

A totally different mechanism.

The text does note that they have pretty long half -lives, so next day drowsiness and concerns about driving safety are definitely a factor.

And finally, in this section, we have the melatonin agonists.

Ramaltion and tessimaltion.

So these aren't sedatives in the classic sense.

No.

They are agonists at melatonin receptors in the suprachiasmatic nucleus.

They help reset the body's internal biological clock, the circadian rhythm.

Ramaltion is for sleep -onset insomnia.

The text notes it has no abuse potential, which is a big deal.

It's not a scheduled drug.

Right.

But you have to watch out for drug interactions.

The book specifically wants not to use it with fluvoxibin, an antidepressant that is a pertinent CYP1A2 inhibitor.

Why is that?

It can raise the levels of ramaltion by 70 -fold.

A massive, massive interaction.

Wow.

Okay.

What about tessimaltion?

This one is really specific.

It is.

It's approved specifically for non -24 -hour sleep -wait disorder.

Which primarily affects people who are totally blind.

Yes.

Without any light perception to cue their brain, their internal clock can't sync up with the 24 -hour day.

It just drifts.

And the text mentions a stealth marketing campaign for this.

It does.

Commercials that were designed to educate the public and find potential patients by talking about the rare disorder itself without ever explicitly naming the drug.

Very clever.

It is.

All right, that brings us to our last category.

Section seven, the non -sedating anxiolytic drugs.

The main player here, and it's a unique one, is buspirone.

So how does it relieve anxiety if it's not sedating?

It's not a benzo.

It doesn't touch the GABA receptor at all.

Its mechanism is completely different.

It is a partial agonist at serotonin 5 -HT1A receptors.

So it works on the serotonin system, more like an antidepressant.

Very similar concept.

And because of this, it can relieve anxiety without causing sedation, amnesia, motor impairment, or tolerance.

It's a great option for generalized anxiety disorder.

So what's the catch?

Why isn't it used for everything?

The catch is that it's slow.

Very slow.

It takes three to four weeks to start working.

So you absolutely cannot use buspirone for a panic attack.

It will do nothing for you in the moment.

It's for chronic management, not acute relief.

And the very final drug mentioned,

propranolol.

The beta blocker, again.

We mentioned it for stage fright.

And again, it works by blocking the peripheral symptoms.

Exactly.

It stops the tachycardia, the sweating, the tremors.

It doesn't stop the worry in your head, but if your body isn't physically freaking out, it helps you get through the performance.

It breaks that vicious feedback loop of anxiety.

So we have covered the entire chapter.

An incredible amount of information.

Let's try to synthesize this at the end.

I think if you take one single thing away from this deep dive, it should be the core safety difference between the two oldest classes.

Benzodiazepines versus barbiturates.

Yes.

Benzodiazepines have a sealing effect.

Because they increase the frequency of channel opening and they need GABA to work.

Right, barbiturates have no sealing.

Because they increase the duration of the opening and at high doses, they can open the channel all by themselves.

And that one mechanistic difference explains almost the entire modern history of why we moved away from barbiturates for anxiety and insomnia.

Absolutely.

The second big takeaway.

I'd say it's the metabolism lesson.

For elderly patients or anyone with liver impairment, stick to the clean phase two drugs,

lorazepam, oxazepam, temazepam, to avoid that dangerous accumulation of active metabolites.

And finally, for sleep, if the goal is to preserve the natural architecture, to get that restorative REM and deep sleep.

Then you should be looking towards the Z drugs or the newer agents like the orexin antagonists rather than the older benzodiazepines which disrupt that architecture.

It's all about choosing the right tool, the right mechanism for the right patient and the right problem.

That's pharmacology in a nutshell.

Well, that brings us to the end of our deep dive into chapter 19.

It is a complex and really dense pharmacological world, but hopefully we've made those pathways and mechanisms a little clearer for you.

It's fascinating stuff, isn't it?

It really is.

Thank you so much for listening.

This has been the Last Minute Lecture Team signing off.

Stay curious.